CP-31398 dihydrochloride

Cat. No.: HY-18343A Purity: 98.29%: FAQs
Data Sheet SDS COA Handling Instructions

CP-31398 dihydrochloride stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53.

For research use only. We do not sell to patients.

CP-31398 dihydrochloride Chemical Structure

CAS No. : 1217195-61-3

Size	Price	Stock	Quantity
1 mg	USD 41	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 88	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 143	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 275	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 440	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 715	Get quote	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

CP-31398 dihydrochloride stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53^[1]^[2]^[3].

In Vitro

CP-31398 (36.75 μM, 16 h) induces p21 in p53-mutant cells^[1].
CP-31398 (15 μg/mL, 20 hours) could induce apoptosis and cell cycle arrest in SW480 cells^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	Saos-2 cells expressing transfected mutant p53.
Concentration:	36.75 μM.
Incubation Time:	16 h.
Result:	Induction of p21 in cells expressing only mutant p53.

Western Blot Analysis^[3]

Cell Line:	LN-18 and U87MG cells.
Concentration:	36 μM.
Incubation Time:	16 h.
Result:	Decreased the levels of procaspase 3 and induced cleavage of caspase 7.

In Vivo

CP-31398 (100 mg/kg, orally) exhibits significant anti-tumor activity in mice models^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Small human tumor xenografts in mice^[1].
Dosage:	100 mg/kg.
Administration:	Orally twice daily for 7 days.
Result:	Suppressed A375.S2 tumor growth by -50%.

Molecular Weight

435.39

Appearance

Solid

Formula

C₂₂H₂₈Cl₂N₄O

CAS No.

1217195-61-3

SMILES

CN(C)CCCNC1=C2C=CC=CC2=NC(/C=C/C3=CC=C(OC)C=C3)=N1.[H]Cl.[H]Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Solvent & Solubility

In Vitro:

H₂O : ≥ 100 mg/mL (229.68 mM)

DMSO : 8.33 mg/mL (19.13 mM; ultrasonic and warming and heat to 65°C)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2968 mL	11.4840 mL	22.9679 mL
5 mM	0.4594 mL	2.2968 mL	4.5936 mL
10 mM	0.2297 mL	1.1484 mL	2.2968 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: 0.83 mg/mL (1.91 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 0.83 mg/mL (1.91 mM); Suspended solution; Need ultrasonic

*All of the co-solvents are available by MCE.

Purity & Documentation

Purity: 98.29%

Select Batch:

Data Sheet (273 KB) SDS (393 KB)

COA (245 KB) HNMR (384 KB) RP-HPLC (259 KB) LCMS (127 KB)

Handling Instructions (2659 KB)

References

[1]. B A Foster, et al. Pharmacological rescue of mutant p53 conformation and function. Science. 1999 Dec 24;286(5449):2507-10. [Content Brief]

[2]. Rishu Takimoto, et al. The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis of Human Cancer Cells and Can Stabilize Wild-Type p53 Protein. Cancer Biol Ther. Jan-Feb 2002;1(1):47-55. [Content Brief]

[3]. J Wischhusen, et al. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene. 2003 Nov 13;22(51):8233-45. [Content Brief]